Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR3A | P46098 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359282 | 0.86 | ADRB1 (0.42) | ADRB1HTR2CHTR1AHTR3ACYP1A2 | |
| SCHEMBL18171738 | 0.85 | ACVR1 (0.45) | ADRB1HTR2CHTR1AHTR3ACYP1A2 | |
| SCHEMBL3951662 | 0.82 | ADRB1 (0.47) | ADRB1HTR2CHTR1AHTR3ACYP1A2 | |
| SCHEMBL3951660 | 0.76 | ADRB1 (0.59) | ADRB1HTR2CHTR1AHTR3ACYP1A2 | |
| SCHEMBL27261095 | 0.74 | ADRB1 (0.42) | ADRB1HTR2CHTR3AHTR7USP2 | |
| SCHEMBL5745223 | 0.71 | ADRB1 (0.49) | ADRB1HTR1AHTR3ACYP1A2CYP3A4 | |
| Acetamide SCHEMBL3242644 | 0.70 | ADRB1 (0.51) | ADRB1HTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL1742849 | 0.70 | ADRB1 (0.47) | ADRB1HTR1AHTR3ACYP1A2CYP3A4 | |
| SCHEMBL3192657 | 0.70 | ACVR1 (0.38) | ADRB1HTR2CHTR1AHSP90AA1HSP90AB1 | |
| SCHEMBL20527676 | 0.70 | HTR6 (0.40) | ADRB1HTR1AHTR3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638627-B2 | Imatinib hydrochloride; reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidineamine with 4-(4-methyl-piperazinomethyl)benzoyl chloride; improved reduction step to simplify, increase yield, improve purity | CIPLA LIMITED (IN) | 2009-12-29 | — | — | US | disclosed |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | CIPLA LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | ABL1, ABL2, MET | ADRB1 2797/4885HTR2C 426/4885HTR1A 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.